In This Section

Program

Please note that this meeting will take place as an in-person event in Boston and will not live-stream content for virtual participation. The meeting content will be recorded and made available as an on-demand program after the conference. Registration details

CME credit is available for in-person attendance for the designated sessions. On-demand presentations are not eligible for CME.

All presentations are scheduled to be live, in-person presentations at the date and time specified below unless noted otherwise.  Program is subject to change. 

[R] – Remote Presentation

Thursday, June 23, 2022

Welcome and Opening Keynote Session
Plenary Session 1: CAR-T


Friday, June 24, 2022

Special Session 1: Initial Treatment of DLBCL: Are We in a New Era?
Plenary Session 2: Evolution of Liquid Biopsies for Lymphoma
Plenary Session 3: Germinal Center Biology
Plenary Session 4: Epigenetics
Plenary Session 5: Modeling for Pre-clinical


Saturday, June 25, 2022

Special Session 2: Mantle Cell Lymphoma
Plenary Session 6: DLBCL: Genomics Toward Precision Therapy
Plenary Session 7: FL and CLL Evolution and Transformation
Special Session 3: TFH T-cell Lymphomas
Plenary Session 8: New Technologies
Plenary Session 9: Immune Evasion in Hodgkin and Non-Hodgkin Lymphomas
Special Session 4: Industry Roundtable

Sunday, June 26, 2022

Special Session 5: AYA Lymphomas
Plenary Session 10: Metabolism and Immunometabolism in Lymphoid Malignancies: A New Target?
Plenary Session 11: Moving Beyond PET: Functional Imaging in Lymphoma
Plenary Session 12: Exploiting NK Cell-therapy in Lymphomas
Closing Comments and Departure

Thursday, June 23, 2022

Registration
12-7 pm
CME Icon
Welcome and Opening Keynote Session
3-5 p.m.

Welcome and Introduction of Keynote Speaker
Riccardo Dalla-Favera, Columbia University, New York, New York

Therapeutic vulnerabilities uncovered by B-cell/stromal crosstalk
Karin Tarte, University of Rennes, Rennes, France

Introduction of Keynote Speaker
Riccardo Dalla-Favera

Integrating bispecific antibodies into lymphoma therapy [R]
Adrian U. Wiestner, National Heart, Lung, and Blood Institute, Bethesda, Maryland

Panel Discussion

Break
5-5:30 p.m.
CME Icon
Plenary Session 1: CAR-T
Session Chair: Sattva S. Neelapu, The University of Texas MD Anderson Cancer Center, Houston, Texas
5:30-7 p.m.

Lessons from CD19 CAR T-cell therapy in B-cell non-Hodgkin lymphoma
Sattva S. Neelapu

Anti-CD19 chimeric antigen receptor T-cells in CLL: A decade in review
Jan Joseph Melenhorst, Cleveland Clinic Lerner Research Institute, Cleveland, Ohio

Challenge accepted: CAR-T cells for T-cell malignancies                                                                              
Rayne H. Rouce, Baylor College of Medicine, Houston, Texas

Panel Discussion

Opening Reception
7-9 p.m.

Friday, June 24, 2022

Breakfast
7-8 a.m.
CME Icon
Special Session 1: Initial Treatment of DLBCL: Are We in a New Era?
Session Chair: Laurie H. Sehn, BC Cancer, Vancouver, BC, Canada
7:30-8:30 a.m.

Molecular classification of DLBCL: Utlilty and barriers to implementation
Grzegorz S. Nowakowski, Mayo Clinic College of Medicine and Science, Rochester, Minnesota

Is there a new one-size-fits-all standard of care in DLBCL?
Laurie H. Sehn

Panel Discussion

Break
8:30-8:45 a.m.
CME Icon
Plenary Session 2: Evolution of Liquid Biopsies for Lymphoma
Session Chair: Davide Rossi, Institute of Oncology Research, Bellinzona, Switzerland
8:45-10:15 a.m.

Understanding the biology of classic Hodgkin lymphoma using circulating tumor DNA
Davide Rossi, Institute of Oncology Research, Bellinzona, Switzerland

Circulating tumor DNA profiling for noninvasive disease detection and MRD monitoring in patients with CNS lymphoma
Florian Scherer, University Medical Center Freiburg, Freiburg, Germany

Next generation methods for disease detection and characterization from
circulating tumor DNA [R]

David M. Kurtz, Stanford University Medical Center, Stanford, California

Panel Discussion

Break
10:15-10:30 a.m.
CME Icon
Plenary Session 3: Germinal Center Biology
Session Chair: Gabriel D. Victora, The Rockefeller University, New York, New York
10:30 a.m.-12 p.m.

T cell help and B cell selection in germinal centers [R]
Gabriel D. Victora

Human germinal center responses to vaccination
Michela Locci, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania

Lymphoma mutations in the evolution of pathogenic autoantibodies [R]
Joanne Reed, The Westmead Institute for Medical Research, Westmead, NSW, Australia

Panel Discussion

Box lunch available
12-1:30 p.m.
CME Icon
Plenary Session 4: Epigenetics
Session Chair: Laura Pasqualucci, Columbia University Irving Comprehensive Cancer Center, New York, New York
1:30-3 P.M.

BAF complex deregulation in B-cell lymphoma
Michael R. Green, The University of Texas MD Anderson Cancer Center, Houston, Texas

Novel interactions between epigenetic regulators altered in B cell lymphoma
Laura Pasqualucci, Columbia University Irving Comprehensive Cancer Center,
New York, New York

How to leverage epigenetic therapeutic interventions in FL?
Gilles Salles, Memorial Sloan Kettering Cancer Center, New York, New York

Panel Discussion

Break
3-3:15 p.m.
CME Icon
Plenary Session 5: Modeling for Pre-clinical
Session Chair: Giorgio Inghirami, Weill Cornell Medicine, New York, New York
3:15-4:45 P.M.

Pre-clinical investigation using patient-derived xenograft modeling of aggressive and indolent B-cell lymphomas
Abner Louissaint, Massachusetts General Hospital, Boston, Massachusetts

Modeling EZH2 mutant follicular lymphomas
Wendy Béguelin, Weill Cornell Medicine, New York, New York

Preclinical data in MCL
Michael Wang, The University of Texas MD Anderson Cancer Center, Houston, Texas

Panel Discussion

Poster Session / Reception
5-7 p.m.

Saturday, June 25, 2022

Breakfast
7-8 a.m.
CME Icon
Special Session 2: Mantle Cell Lymphoma
Session Chair: Francesco Bertoni, Institute of Oncology Research, Bellinzona, Switzerland
7:30-8:30 a.m.

Dynamic changes in gene mutational landscape with preservation of core mutations in mantle cell lymphoma
Mariusz A. Wasik, Fox Chase Cancer Center, Philadelphia, Pennsylvania

Targeting SOX11 in mantle cell lymphoma [R]
Samir Parekh, Icahn School of Medicine at Mount Sinai, New York, New York

Panel Discussion

Break
8:30-8:45 a.m.
CME Icon
Plenary Session 6: DLBCL: Genomics Toward Precision Therapy
Session Chair: Riccardo Dalla-Favera, Columbia University, New York, New York
8:45-10:15 A.M.

Leveraging functional and structural genomics for precision medicine
James D. Phelan, National Cancer Institute, Bethesda, Maryland

Understanding lymphoma biology and improving classification through comprehensive sequencing
Ryan D. Morin, Simon Fraser University, Vancouver, BC, Canada

Pervasive hypermutation of super-enhancers dysregulates oncogene expression in DLBCL
Riccardo Dalla-Favera

Panel Discussion

Break
10:15-10:30 a.m.
CME Icon
Plenary Session 7: FL and CLL Evolution and Transformation
Session Chair: Catherine J. Wu, Dana Farber Cancer Institute, Boston, Massachusetts
10:30 A.M.-12 P.M.

Human genetic studies: CLL and transformation
Catherine J. Wu

Understanding CLL and Richter’s syndrome biology through mouse models of human genetics
Elisa ten Hacken, Dana Farber Cancer Institute, Boston, Massachusetts

Follicular lymphoma and transformation
Jessica Okosun, Queen Mary University of London, London, England

Panel Discussion

Box Lunch Available 
12-1:30 p.m.
CME Icon
Special Session 3: T-cell Lymphomas 
Session Chair: Teresa Palomero, Columbia University, New York, New York
12:30-1:30 pm 

Genomic alterations and mouse models in PTCL                                                
Teresa Palomero

The role of PD1 in t cell lymphomas
Jaehyuk Choi, Northwestern University, Chicago, Illinois

Panel Discussion

CME Icon
Plenary Session 8: New Technologies
Session Chair: Kojo S.J Elenitoba-Johnson, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania
1:45-3:15 P.M.

Title to be announced
Kojo S.J. Elenitoba-Johnson

A multi-scale, multiomic atlas of human normal and follicular lymphoma lymph nodes      
Andrea Radtke, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland

Elucidation of lymphoma biology by proteogenomics [R]
Thomas Oellerich, Goethe University Hospital, Frankfurt, Germany

Panel Discussion

Break
3:15-3:30 p.m.
CME Icon
Plenary Session 9: Immune Evasion in Hodgkin and Non-Hodgkin Lymphomas
Session Chair: Margaret A. Shipp, Dana Farber Cancer Institute, Boston, Massachusetts
3:30-5 P.M.

Genetic bases of immune evasion in lymphoid malignancies
Margaret A. Shipp

New imaging approaches to characterize the intact tumor microenvironment
Scott J. Rodig, Brigham and Women’s Hospital, Boston, Massachusetts

The DLBCL immune landscape: Evidence for immune surveillance, evasion, and exclusion
Justin P. Kline, University of Chicago, Chicago, Illinois

Panel Discussion

Special Session 4: Industry Roundtable
Session Chair: Anas Younes, AstraZeneca, New York, New York
5:30-6:30 p.m.

Adam S. Crystal, C4 Therapeutics, Watertown, Massachusetts [R]
Gwenn Hansen, Nurix Therapeutics, Inc., San Francisco, California
Yu-Waye (Wayne) Chu, Fate Therapeutics, San Diego, California

Panel Discussion

SUnday, June 26, 2022

Breakfast
7-8 a.m.
CME Icon
Special Session 5: AYA Lymphomas 
Session Chair: Andrew M. Evens, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey
7:30-8:30 a.m.

Pathology of AYA lymphomas: Creating a roadmap for translational research
Megan S. Lim, Perelman School of Medicine University of Pennsylvania, Philadelphia, Pennsylvania

Unmet clinical research questions in AYA lymphomas
Jamie E. Flerlage, St. Jude Children’s Research Hospital, Nashville, Tennessee

Panel Discussion

Break
8:30-8:45 a.m.
CME Icon
Plenary Session 10: Metabolism and Immunometabolism in Lymphoid Malignancies: A New Target?
Session Chair: Ari M. Melnick, Weill Cornell Medical College / Cornell University, New York, New York
8:45-10:15 A.M.

Metabolic communication within lymphoma microenvironments
Leandro C. Cerchietti, Weill Cornell Medicine, New York, New York

Title to be announced
Nika N. Danial, Dana-Farber Cancer Institute, Boston, Massachusetts

Multi-omic analysis reveals B-cell stimulus-specific oncogenic pathway responses
and targets

Benjamin E. Gewurz, Brigham and Women’s Hospital, Boston, Massachusetts

Panel Discussion

Break
10:15-10:30 a.m.
CME Icon
Plenary Session 11: Moving Beyond PET: Functional Imaging in Lymphoma
Session Chair: Judith Trotman, University of Sydney, Sydney, Australia
10:30 A.M.-12 P.M.

Future developments in PET imaging in lymphoma    
Heiko Schoder, Memorial Sloan Kettering Cancer Center, New York, New York

FDG-PET in FL: Staging, response assessment, and beyond                                        
Stefano Luminari, University of Modena and Reggio Emilia, Modena, Italy

PET in diffuse large B cell lymphoma
Judith Trotman

Panel Discussion

Break
12-12:15 p.m.
CME Icon
Plenary Session 12: Exploiting NK Cell-therapy in Lymphomas
Session Chair: Catherine Bollard, Children’s National Hospital, Washington, DC
12:15-1:45 P.M.

Development of nicotinamide enhanced NK cell therapeutics for lymphoma
Veronika S. Bachanova, University of Minnesota, Minneapolis, Minnesota

Driving innate recognition and engineering memory-like NK cells in lymphoma
Melissa M. Berrien-Elliott, Washington University School of Medicine, St. Louis, Missouri

IL-21 expanded, off the shelf, third-party NK cells: Novel therapies for lymphoma
John C. Reneau, The Ohio State University Wexner Medical Center, Columbus, Ohio

Panel Discussion

Closing Comments and Departure
1:45 p.m.

Riccardo Dalla-Favera, Columbia University, New York, New York

Program times subject to change